febuxostat sold brand names uloric adenuric among others medication used longterm treat gout due high uric acid generally recommended people take initially started medications nsaids often recommended prevent gout taken common side effects include liver problems nausea joint pain serious side effects include increased risk death compared allopurinol syndrome use recommended pregnancy inhibits xanthine oxidase thus reducing production uric acid febuxostat approved medical use european union united states generic version approved febuxostat used treat chronic gout febuxostat typically recommended people tolerate national institute health clinical excellence concluded febuxostat effective standard doses allopurinol effective higher doses adverse effects associated febuxostat therapy include nausea diarrhea arthralgia headache increased hepatic serum enzyme levels november fda issued safety alert indicating preliminary results safety clinical trial showed increased risk heartrelated death febuxostat compared allopurinol people history cardiovascular fda required takeda conduct safety study medicine approved febuxostat drug labels already carry warning precaution cardiovascular events clinical trials conducted approval showed higher rate heartrelated problems patients treated febuxostat compared allopurinol problems included heart attacks strokes heartrelated deaths result fda required additional safety clinical trial drug approved market better understand differences trial finished recentlywhen safety trial conducted patients gout treated either febuxostat allopurinol primary outcome combination heartrelated death nondeadly heart attack nondeadly stroke condition inadequate blood supply heart requiring urgent surgery preliminary results show overall febuxostat increase risk combined events compared allopurinol however outcomes evaluated separately febuxostat showed increased risk heartrelated deaths death febuxostat contraindicated concomitant use theophylline chemotherapeutic agents namely azathioprine could increase blood plasma concentrations drugs thereby febuxostat nonpurineselective inhibitor xanthine works noncompetitively blocking molybdenum pterin center active site xanthine oxidase xanthine oxidase needed oxidize successively hypoxanthine xanthine uric acid thus febuxostat inhibits xanthine oxidase thereby reducing production uric acid febuxostat inhibits oxidized reduced forms xanthine oxidase virtue tight binding molybdenum pterin oral intake least febuxostat dose absorbed gut highest blood plasma concentrations reached minutes taken together fatty meal febuxostat reaches lower concentrations body considered clinically relevant bloodstream substance bound plasma protein albumin active metabolites bound plasma febuxostat three active metabolites humans formed mainly number cytochrome liver enzymes one dicarboxylic acid two hydroxylated derivatives well original drug glucuronidated mainly enzymes febuxostat metabolites eliminated via urine total substance comprising unchanged febuxostat febuxostat glucuronide active metabolites glucuronides unknown entities via faeces unchanged febuxostat glucuronide active metabolites glucuronides unknown entities elimination halflife five eight febuxostat discovered scientists japanese pharmaceutical company teijin teijin partnered drug tap pharmaceuticals us ipsen ipsen obtained marketing approval febuxostat european medicines agency april takeda obtained fda approval february teijin obtained approval japanese authorities ipsen exclusively licensed european rights menarini teijin partnered astellas distribution china southeast uk nice found febuxostat higher costbenefit ratio allopurinol basis recommended febuxostat secondline drug people use became generic united states cost per month opposed allopurinol per febuxostat marketed adenuric europe australia new zealand pakistan pakistan launched solace pharmaceuticals sister subsidiary sjg uloric us goturic goutex latin america feburic japan donifoxate egypt generic several countries available many names httpsenwikipediaorgwikiadenuric